Assembly Biosciences (ASMB) EBITDA (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly EBITDA of -$11.4 million for Q1 2026, down 14.37% year-over-year from -$13.3 million in Q1 2025, and down 157.43% quarter-over-quarter from $19.8 million in Q4 2025.
Assembly Biosciences (ASMB) EBITDA (2010 - 2026) Analysis & Trends
Assembly Biosciences' EBITDA history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.
- In Q1 2026, EBITDA fell 14.37% year-over-year to -$11.4 million; the TTM figure through Mar 2026 stood at -$13.5 million (up 69.65% YoY), while the FY2025 annual figure was -$12.1 million, up 73.32% from the prior year.
- EBITDA for Q1 2026 stood at -$11.4 million, down from $19.8 million in the prior quarter.
- The five-year high for EBITDA was $19.8 million in Q4 2025, with the low at -$24.6 million in Q2 2022.
- The 5-year median for EBITDA is -$12.2 million (2024), against an average of -$13.4 million.
- The sharpest annual moves came in 2022 and 2025: EBITDA slipped 23.98% in 2022, then surged 271.69% in 2025.
- Assembly Biosciences' EBITDA stood at -$23.0 million in 2022, then soared by 45.38% to -$12.6 million in 2023, then grew by 8.12% to -$11.5 million in 2024, then soared by 271.69% to $19.8 million in 2025, then plunged by 157.43% to -$11.4 million in 2026.
- Business Quant data shows ASMB's EBITDA at -$11.4 million in Q1 2026, $19.8 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | -6.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.34 Mn |
| Mar 31, 2026 | -11.37 Mn |
| Dec 31, 2025 | 19.80 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Jun 30, 2025 | -11.09 Mn |
| Mar 31, 2025 | -9.94 Mn |
| Dec 31, 2024 | -11.53 Mn |
| Sep 30, 2024 | -10.96 Mn |
| Jun 30, 2024 | -12.20 Mn |
| Mar 31, 2024 | -10.73 Mn |
| Dec 31, 2023 | -12.55 Mn |
| Sep 30, 2023 | -15.05 Mn |
| Jun 30, 2023 | -17.49 Mn |
| Mar 31, 2023 | -19.56 Mn |
| Dec 31, 2022 | -22.98 Mn |
| Sep 30, 2022 | -23.40 Mn |
| Jun 30, 2022 | -24.57 Mn |
| Mar 31, 2022 | -23.16 Mn |
| Dec 31, 2021 | -62.89 Mn |
| Sep 30, 2021 | -18.88 Mn |